About this medicine

Gabapentin may appear alongside psychiatric treatment because pain and epilepsy can coexist with mental-health conditions. Its product licence should not be confused with a general licence for anxiety or insomnia.

What is this medicine used for?

Neurontin covers adjunctive partial-seizure treatment from age 6, monotherapy from age 12, and peripheral neuropathic pain in adults. Neither anxiety nor bipolar disorder is listed in the checked indications.

UK alcohol-treatment guidance does not recommend routine gabapentin use for relapse prevention: evidence and national practice differ from some international use. An off-label discussion therefore needs its own evidence review, not an assumed psychiatric licence.

The liquid’s licence covers adjunctive partial-seizure treatment from six, monotherapy from twelve, and adult peripheral neuropathic pain. It does not add a psychiatric indication. Kidney-related dose adjustment and the dependence, withdrawal and breathing precautions still apply when gabapentin is taken as a liquid.

Which warning signs need help?

Severe breathing difficulty, unresponsiveness or a serious allergic reaction needs emergency help. Seek urgent assessment for a widespread rash with fever, jaundice, persistent severe abdominal pain or suicidal thoughts. Dependence and withdrawal are possible even during prescribed treatment.

How do I take it safely?

For adults and adolescents aged at least 12, the checked SmPC describes a gradual start of 300 mg on day one, 300 mg twice on day two and 300 mg three times on day three. Slower or renal-adjusted schedules may be needed. This is not a psychiatric dosing recommendation.

The adult licensed regimens can reach 3,600 mg/day in divided doses, but kidney impairment may require substantially less. This maximum is not a target. Childhood epilepsy dosing is weight-based; adult instructions must not be reused.

Gabapentin Thame is a 50 mg/ml liquid, supplied with an oral syringe. It can be taken with or without food; prescribed milligrams and measured millilitres are different quantities. The bottle is discarded 30 days after opening. Keep it below 25°C, without refrigeration or freezing.

What side effects should I know about?

Sleepiness, dizziness, nausea, diarrhoea, swelling, blurred vision and weight gain are recognised effects. Discuss persistent symptoms rather than increasing or stopping doses independently.

Who needs extra care with this medicine?

Older people and those with respiratory, neurological or kidney disease may be more vulnerable to respiratory depression. Prior dependence or withdrawal problems should be discussed without stigma.

Can it affect my other medicines?

Opioids and other central-nervous-system depressants can add to sedation and breathing problems. Every new medicine, including non-prescription products, should be checked for interactions.

Aluminium- or magnesium-containing antacids reduce absorption: the product advises taking gabapentin at least two hours after these antacids. This spacing does not remove the breathing risk of combining sedating medicines.

What check-ups will I need?

Review the original indication, benefit, kidney function, sedation and signs of tolerance or dependence. The decision to continue should be revisited, with support for eventual withdrawal when appropriate.

Routine gabapentin blood-level testing is not required to optimise treatment. For neuropathic pain lasting beyond five months of treatment, the SmPC calls for reassessment because longer-term trial evidence is limited. Clinical benefit, kidney function and adverse effects remain central.

What about pregnancy, breastfeeding and age?

Pregnancy needs individual review because evidence remains limited. Do not abruptly stop epilepsy treatment. Breastfeeding can be compatible after assessment of a healthy baby, with attention to feeding and alertness.

The current SmPC reports reassuring major-malformation findings from a Nordic study of over 1,700 first-trimester exposures, but observational evidence cannot exclude every risk. Newborn withdrawal has been reported, particularly with opioid co-exposure, and infants may need monitoring.

What if I miss a dose or want to stop?

Withdrawal should follow an individual plan. Current product information gives longer minimum tapers for higher doses; some people need weeks or months. Abrupt stopping can also destabilise seizure control.

How does it work?

Gabapentin attaches to a supporting part of certain calcium channels in nerve cells. These channels help regulate the release of chemical messages, so changing their behavior can influence communication in the nervous system. Despite its name, gabapentin does not work by acting directly like GABA, a brain messenger that usually makes nerve cells less active.

How Brain Cells Communicate

When an electrical signal reaches a nerve ending, calcium can enter through channels in the cell’s membrane. That calcium entry helps trigger the release of neurotransmitters, the chemicals that carry messages to other cells. Each calcium channel has several parts, and some of these parts help control how the channel is positioned or functions. A supporting part is sometimes called an auxiliary subunit.

What is known: Calcium entry is involved in releasing chemical messengers from nerve endings.

What remains uncertain: A change in one channel component does not describe all activity in a pain pathway.

How the process works

  1. Cell activation
  2. Calcium channels
  3. Chemical signaling
Calcium entry is involved in releasing chemical messengers from nerve endings. Simplified illustration of the process; individual responses vary.
About this illustration

Cell activation; Calcium channels; Chemical signaling. A change in one channel component does not describe all activity in a pain pathway.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Gabapentin binds strongly to an auxiliary subunit called alpha-2-delta. The binding is well established in laboratory studies, but the precise chain of events connecting it to pain relief and seizure control is not fully understood.

What is known: Gabapentin binds to alpha-2-delta subunits of voltage-activated calcium channels.

What remains uncertain: The label does not establish every step between binding and clinical benefit.

How the process works

  1. Gabapentin
  2. Alpha-2-delta site
  3. Altered signaling
Gabapentin binds to alpha-2-delta subunits of voltage-activated calcium channels. Simplified illustration of the process; individual responses vary.
About this illustration

Gabapentin; Alpha-2-delta site; Altered signaling. The label does not establish every step between binding and clinical benefit.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

Gabapentin resembles GABA in part of its chemical structure, but chemical resemblance does not mean the two substances act in the same way. The label reports no direct effect on GABA binding, uptake or breakdown. Gabapentin itself is active without needing substantial chemical conversion, and the kidneys remove it largely unchanged. The amount absorbed from the digestive tract also changes in a way that is not directly proportional to the amount taken.

What is known: Gabapentin is active without needing substantial chemical conversion.

What remains uncertain: Its chemical similarity to GABA does not establish GABA-receptor action or interchangeability with pregabalin.

How the process works

  1. Parent molecule
  2. Exposure varies
  3. Clinical assessment
Gabapentin is active without needing substantial chemical conversion. Simplified illustration of the process; individual responses vary.
About this illustration

Parent molecule; Exposure varies; Clinical assessment. Its chemical similarity to GABA does not establish GABA-receptor action or interchangeability with pregabalin.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Dizziness and sleepiness can affect balance and driving. Some people notice swelling, weight gain or memory difficulties.

How does my body process it?

Gabapentin leaves the body unchanged through the kidneys. Reduced kidney function slows clearance and requires an adjusted regimen.

How do treatment options differ?

Pregabalin has a UK adult GAD licence; the checked gabapentin product does not. A related molecular target does not establish equal indications or equivalent doses.

A closer look at the science

It binds the alpha-2-delta subunit of voltage-gated calcium channels. Despite its name and structure, it does not bind GABA-A or GABA-B receptors.

Gabapentin is a small molecule structurally related to GABA, with a cyclohexane ring. Similarity to GABA does not make it a GABA-receptor agonist.

Chemical formula: C9H17NO2

The formula represents nine carbon, seventeen hydrogen, one nitrogen, and two oxygen atoms in the gabapentin parent molecule. The drawing is not gabapentin enacarbil, a different prodrug.

Verified PubChem two-dimensional structure of gabapentin, CID 3446.
NCBI PubChem CID 3446: Gabapentin parent compound. Lines indicate bonds; unlabeled corners indicate carbon and many hydrogens are omitted. Not a receptor-binding pose.

Parent molecule connectivity; no product release rate, clinical response or dose equivalence follows from this drawing.

How was this medicine developed?

MHRA warnings developed to include respiratory depression and, in January 2026, clearer communication about dependence and withdrawal. These updates should inform current education.

Sources and References

  1. Neurontin 100 mg capsules: SmPC, sections 4–5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Neurontin capsules and tablets: patient leaflet, sections 1–4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Neurontin 600 mg tablets: SmPC, sections 2–4.2

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Side effects of gabapentin

    Scope: NHS website medicines information (England); not a guarantee of identical services across UK nations.

  5. Gabapentin: pregnancy, breastfeeding and fertility

    Scope: NHS website medicines information (England); not a guarantee of identical services across UK nations.

  6. Gabapentin: risk of severe respiratory depression

    Scope: United Kingdom.

  7. Improving information supplied with gabapentinoids, benzodiazepines and z-drugs (8 January 2026)

    Scope: United Kingdom.

  8. Lyrica 75 mg capsules: SmPC, section 4.1

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  9. UK clinical guidelines for alcohol treatment — chapter 10, pharmacological interventions

    Scope: United Kingdom: England, Scotland, Wales and Northern Ireland.

  10. Gabapentin Thame 50 mg/ml oral solution — SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; named product information.

  11. Neurontin capsules, tablets and oral solution: current prescribing information
  12. Neurontin: FDA prescribing information, April 2025
  13. Gabapentin: verified neutral parent, PubChem CID 3446
  14. All Opioid Pain Medicines: Drug Safety Communication - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use | FDA
  15. New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines | FDA

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top